What are the implications of the NICE Quality Standards?
The updated and expanded NICE quality standards should be used in all care settings to audit and improve services for people with chronic heart failure, according to Dr… read more.
The updated and expanded NICE quality standards should be used in all care settings to audit and improve services for people with chronic heart failure, according to Dr… read more.
Dr Rani Khatib is a consultant pharmacist in cardiology and cardiovascular research and associate professor at the University of Leeds. As a member of the NICE Guideline Development… read more.
An automated system that flags which patients could most benefit from an underused yet life-saving cardiology drug more than doubled new prescriptions, according to a pilot program test… read more.
Hundreds of thousands of Americans with heart failure are sick enough to benefit from a transplant, yet only around 4,000 heart transplants are performed annually. One reason for… read more.
Adjunctive dapagliflozin therapy appears to improve outcomes in heart failure patients without regard to frailty status at initiation of treatment. These findings appeared on April 26, 2022 in… read more.
Heart transplantation can be a lifesaving operation for patients with end-stage heart failure. However, many patients experience organ transplant rejection, in which the immune system begins attacking the… read more.
Jardiance (empagliflozin), from Eli Lilly and Boehringer, reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline… read more.
Not too long ago the idea of taking, for instance a skin cell and transforming it into a muscle cell was unthinkable. About 10 years ago, however, revolutionary… read more.
Jardiance (empagliflozin) 10 mg has been approved by the FDA to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with… read more.
Treatment with statins of patients with heart failure is linked to a reduced risk of cancer, researchers reported on June 23, 2021 in the European Heart Journal. Lead investigator… read more.
Merck Inc., has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). In the… read more.
The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer… read more.